Bharat Biotech's nasal vaccine gets approval for Phase II and III clinical trials

Bharat Biotech's Nasal Vaccine has been approved for Phase II and III clinical trials.

Nasal Vaccine: The first nasal (given via nasal spray) vaccine developed by Bharat Biotech against Kovid-19 has been approved for the second, third phase of experimental trials. The Department of Biotechnology has given this information. The first phase of the trial has been done on people between the ages of 18 and 60, the statement said.

The intranasal vaccine is BBV154, the technology of which was acquired by Bharat Biotech from Washington University in St. Louis. This is the first such Kovid-19 vaccine that will have clinical trials on humans in India.

If you want to Read Breaking news in Hindi  like this then check it out

DBT said, "The company has informed that the vaccine doses administered to healthy participants in the first phase of clinical trials have been well accepted by the body. No serious adverse effects are known.” The vaccine was found to be safe even in prior clinical studies. In animal studies, the vaccine was successful in producing high levels of antibodies. 

read More;- Bollywood news in Hindi

Let us inform that at present, three vaccines are available in the country for the common people, Bharat Biotech's Covaccine, Serum Institute's Kovishield and Russia's Sputnik V. The government has also approved Moderna's mRNA vaccine and Johnson & Johnson's single dose vaccine for use.

So far 52.95 crore doses of anti-corona vaccine have been given in the country. According to the Ministry of Health, on Thursday, 27,83,649 people in the age group of 18 to 44 years were given the first dose and 4,85,193 were given the second dose.

Sponsor Ads

• Ad Space Available - Rent it Now!

Report this Page

Created on Aug 13th 2021 10:53. Viewed 251 times.

Share on APSense

Comments